Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their ...

While there have been many sober warnings about AI and recursive self-improvement, Arianna Huffington argues that it is a ...

Recursion Pharmaceuticals (RXRX) closed at $3.23 in the latest trading session, marking a +2.22% move from the prior day.

Anthropic published an interesting blog post titled "When AI Builds Itself." a couple of days ago, and if you work in financial services and haven't read it, stop what you're doing. The piece ...

Recursion Pharmaceuticals combines artificial intelligence, automation, and biotechnology research across multiple ...

Recursive self-improvement AI now has a co-evolving evaluator: a Cambridge and NVIDIA preprint introduces the Red Queen Gödel ...

Governments currently lack the frameworks, technical expertise, and speed to evaluate and regulate such advanced AI. The ...

Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from ...

Microsoft, meanwhile, is trying to turn the trend towards recursive self-improvement into a sales pitch for enterprise AI. In ...

In Barrie's Peter Pan, Wendy sewed Peter's mischievous shadow back on his feet. Wendy saw what was incomplete and chose to ...

A new VentureBeat survey of 145 enterprises finds most have hedged their AI model strategy since the Fable 5 blackout, but ...